company background image
0A4Y logo

AIM ImmunoTech LSE:0A4Y Stock Report

Last Price

US$0.21

Market Cap

US$13.4m

7D

-9.1%

1Y

-55.4%

Updated

23 Nov, 2024

Data

Company Financials +

0A4Y Stock Overview

An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More details

0A4Y fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

AIM ImmunoTech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AIM ImmunoTech
Historical stock prices
Current Share PriceUS$0.21
52 Week HighUS$0.60
52 Week LowUS$0.18
Beta-0.36
11 Month Change-15.64%
3 Month Change-42.24%
1 Year Change-55.37%
33 Year Change-85.47%
5 Year Changen/a
Change since IPO-99.15%

Recent News & Updates

Recent updates

Shareholder Returns

0A4YGB BiotechsGB Market
7D-9.1%0.3%2.2%
1Y-55.4%-18.3%8.0%

Return vs Industry: 0A4Y underperformed the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0A4Y underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0A4Y's price volatile compared to industry and market?
0A4Y volatility
0A4Y Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine 0A4Y's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
196627Thomas Equelsaimimmuno.com

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

AIM ImmunoTech Inc. Fundamentals Summary

How do AIM ImmunoTech's earnings and revenue compare to its market cap?
0A4Y fundamental statistics
Market capUS$13.38m
Earnings (TTM)-US$23.93m
Revenue (TTM)US$190.00k

70.4x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4Y income statement (TTM)
RevenueUS$190.00k
Cost of RevenueUS$36.00k
Gross ProfitUS$154.00k
Other ExpensesUS$24.08m
Earnings-US$23.93m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin81.05%
Net Profit Margin-12,594.21%
Debt/Equity Ratio93.8%

How did 0A4Y perform over the long term?

See historical performance and comparison